2024
Distinct epigenetic and transcriptional profiles of Epstein-Barr virus (EBV) positive and negative primary CNS lymphomas
Hai L, Friedel D, Hinz F, Hoffmann D, Doubrovinskaia S, Rohdjess H, Weidenauer K, Denisova E, Scheffler G, Kessler T, Kourtesakis A, Herold-Mende C, Henegariu O, Baehring J, Dietrich J, Brors B, Wick W, Sahm F, Kaulen L. Distinct epigenetic and transcriptional profiles of Epstein-Barr virus (EBV) positive and negative primary CNS lymphomas. Neuro-Oncology 2024, noae251. PMID: 39575767, DOI: 10.1093/neuonc/noae251.Peer-Reviewed Original ResearchPrimary CNS lymphomaEpstein-Barr virusB cell receptorCNS lymphomaTargeted therapyEpigenetic profilesB cellsDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaPromoter region hypermethylationEBV oncogeneEBV lymphomasEBV- tumorsEPIC methylation arrayWnt/beta-catenin signalingEBV diseaseBiological subtypesUnsupervised cluster analysisInterleukin-10Promoter methylationLymphomaSyk kinase activityBrain tumorsMutational landscapeBIOS-03. CLINICAL PRESENTATION, MANAGEMENT, AND OUTCOME IN NEUROLYMPHOMATOSIS: A SYSTEMATIC REVIEW AND ANALYSIS OF INDIVIDUAL PATIENT DATA FROM 459 CASES
Kaulen L, Hielscher T, Doubrovinskaia S, Hoffmann D, Kessler T, Traub B, Baehring J, Wick W. BIOS-03. CLINICAL PRESENTATION, MANAGEMENT, AND OUTCOME IN NEUROLYMPHOMATOSIS: A SYSTEMATIC REVIEW AND ANALYSIS OF INDIVIDUAL PATIENT DATA FROM 459 CASES. Neuro-Oncology 2024, 26: viii38-viii38. PMCID: PMC11552887, DOI: 10.1093/neuonc/noae165.0151.Peer-Reviewed Original ResearchPeripheral nervous systemPrimary NLPrognostic factorsDiagnostic yieldFDG-PETRituximab-based therapyRituximab-based treatmentMedian overall survivalNon-Hodgkin's lymphomaManifestation of malignancyNervous systemTumor-directed therapyMultivariate survival analysisCox proportional hazards modelsTreatment of NLConcurrent systemic diseaseSystematic reviewProportional hazards modelConsensus therapyPainful polyneuropathyLymphomatous infiltrationOverall survivalPerformance statusPrognostic stratificationClinical presentationPATH-35. INTEGRATED GENOMIC ANALYSES OF IMMUNODEFICIENCY-ASSOCIATED EPSTEIN-BARR VIRUS- (EBV) POSITIVE PRIMARY CNS LYMPHOMAS
Kaulen L, Denisova E, Hinz F, Hai L, Friedel D, Henegariu O, Hoffmann D, Ito J, Kourtesakis A, Lehnert P, Doubrovinskaia S, Karschnia P, von Baumgarten L, Kessler T, Baehring J, Brors B, Sahm F, Wick W. PATH-35. INTEGRATED GENOMIC ANALYSES OF IMMUNODEFICIENCY-ASSOCIATED EPSTEIN-BARR VIRUS- (EBV) POSITIVE PRIMARY CNS LYMPHOMAS. Neuro-Oncology 2024, 26: viii186-viii186. PMCID: PMC11553229, DOI: 10.1093/neuonc/noae165.0734.Peer-Reviewed Original ResearchPrimary CNS lymphomaEpstein-Barr virusRNAseq dataSingle nucleotide variantsCopy number variantsComprehensive genetic analysisRNA sequencing dataCopy number gainCNS lymphomaGermline controlTumor microenvironmentNucleotide variantsSequence dataTranscript groupsTargeting motifGenetic analysisGenetic landscapeJAK/STAT signalingCytotoxic T cell responsesRNA sequencingTolerogenic tumor microenvironmentAberrant somatic hypermutationExpression of CD70T regulatory cellsT cell responsesNIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS
Thaw-Poon S, Blondin N, Liu Y, Corbin Z, Baehring J, Omuro A, Moliterno J, Omay S, Fulbright R, de Graaf R, De Feyter H. NIMG-30. DEUTERIUM METABOLIC IMAGING (DMI) SHOWS A STRONG RELATION BETWEEN TUMOR GRADE AND GLUCOSE METABOLISM IN PRIMARY BRAIN TUMORS. Neuro-Oncology 2024, 26: viii201-viii201. PMCID: PMC11553074, DOI: 10.1093/neuonc/noae165.0795.Peer-Reviewed Original ResearchGrade 2 lesionsTumor gradeDeuterium metabolic imagingMetabolic imagingNon-enhancing tumor regionsBrain tumorsTumor-to-brain contrastTumour-specific valuesActive tumor tissueImage contrastVOI-based analysisGrade 4Evaluate disease progressionTesla MRI scannerFDG-PETGrade 3Lesion gradeTumor tissuesDisease progressionDisease stageOral administrationTumorObservational studyNormal brainContrast enhancementP20.12.B INTEGRATED GENETIC ANALYSES OF IMMUNODEFICIENCY-ASSOCIATED EPSTEIN-BARR VIRUS- (EBV) POSITIVE PRIMARY CNS LYMPHOMAS
Kaulen L, Denisova E, Hinz F, Hai L, Friedel D, Henegariu O, Hoffmann D, Ito J, Kourtesakis A, Lehnert P, Doubrovinskaia S, Karschnia P, von Baumgarten L, Kessler T, Baehring J, Brors B, Sahm F, Wick W. P20.12.B INTEGRATED GENETIC ANALYSES OF IMMUNODEFICIENCY-ASSOCIATED EPSTEIN-BARR VIRUS- (EBV) POSITIVE PRIMARY CNS LYMPHOMAS. Neuro-Oncology 2024, 26: v118-v118. PMCID: PMC11485591, DOI: 10.1093/neuonc/noae144.399.Peer-Reviewed Original ResearchPrimary CNS lymphomaEpstein-Barr virusRNAseq dataSingle nucleotide variantsCopy number variantsComprehensive genetic analysisRNA sequencing dataCNS lymphomaCopy number gainTumor microenvironmentGermline controlNucleotide variantsSequence dataTranscript groupsCytotoxic T cell responsesEpstein-Barr virus-positiveTargeting motifGenetic analysisGenetic landscapeJAK/STAT signalingTolerogenic tumor microenvironmentRNA sequencingAberrant somatic hypermutationExpression of CD70T regulatory cellsP12.10.B HYPOKINETIC MOVEMENT DISORDERS FOLLOWING ADOPTIVE IMMUNOTHERAPY WITH BCMA-DIRECTED CAR T-CELLS: A CONSECUTIVE CASE SERIES
Gudera J, Baehring J, Fulbright R, Dietrich J, Karschnia P. P12.10.B HYPOKINETIC MOVEMENT DISORDERS FOLLOWING ADOPTIVE IMMUNOTHERAPY WITH BCMA-DIRECTED CAR T-CELLS: A CONSECUTIVE CASE SERIES. Neuro-Oncology 2024, 26: v68-v68. PMCID: PMC11485477, DOI: 10.1093/neuonc/noae144.223.Peer-Reviewed Original ResearchChimeric antigen receptorCAR-T cellsChimeric antigen receptor T cellsB-cell maturation antigenT cellsParkinsonism-like symptomsChimeric antigen receptor T-cell productsMovement disordersCirculating CAR T cellsHypokinetic movement disordersOn-target/off-tumor toxicityPatient died of sepsisCare of affected patientsRefractory multiple myelomaMedian follow-upConsecutive case seriesT cell productionDegree of suspicionBasal ganglia hypometabolismDiffusion-weighted sequencesMovement symptomsHead of the caudate nucleusAdoptive immunotherapyPatient diedSystemic immunosuppressionP27.10.B FACTORS INFLUENCING TIMELY DIAGNOSIS IN NEUROLYMPHOMATOSIS
Doubrovinskaia S, Egert A, Karschnia P, Scheffler G, Huttner A, Fulbright R, Baehring J, Kaulen L. P27.10.B FACTORS INFLUENCING TIMELY DIAGNOSIS IN NEUROLYMPHOMATOSIS. Neuro-Oncology 2024, 26: v138-v139. PMCID: PMC11485484, DOI: 10.1093/neuonc/noae144.472.Peer-Reviewed Original ResearchNon-Hodgkin's lymphomaPeripheral nervous systemNerve root lesionsDiagnostic intervalRelapse of NHLSymptom onsetAssociated with early diagnosisTertiary referral centerAtypical clinical presentationRoot lesionsCerebrospinal fluid examinationDiagnostic work-upYale Cancer CenterPainful polyneuropathyAsymmetric neuropathyClinical presentationReferral centerFluid examinationQuality control databaseDiagnostic delayFDG-PETPrimary diseaseUnivariate analysisConventional CTNeurolymphomatosisParkinsonism Following Chimeric Antigen Receptor T Cell Therapy
Gudera J, Baehring J, Karschnia P. Parkinsonism Following Chimeric Antigen Receptor T Cell Therapy. JAMA Neurology 2024, 81: 1223-1224. PMID: 39133506, DOI: 10.1001/jamaneurol.2024.2506.Peer-Reviewed Original ResearchFactors influencing timely diagnosis in neurolymphomatosis
Doubrovinskaia S, Egert A, Karschnia P, Scheffler G, Traub B, Galluzzo D, Huttner A, Fulbright R, Baehring J, Kaulen L. Factors influencing timely diagnosis in neurolymphomatosis. Journal Of Neuro-Oncology 2024, 170: 309-317. PMID: 39115616, DOI: 10.1007/s11060-024-04792-2.Peer-Reviewed Original ResearchNon-Hodgkin's lymphomaPeripheral nervous systemDiagnostic intervalNon-Hodgkin lymphoma diagnosisSymptom onset to diagnosisCerebrospinal fluid examinationYale Cancer CenterPainful polyneuropathyAsymmetric neuropathyRare entityMedian intervalFluid examinationQuality control databaseDelayed diagnosisPrimary diseaseUnivariate analysisConventional CTDisease sitesNeurolymphomatosisNeuro-oncologyCancer CenterSecondary diseaseImaging modalitiesNeuroimaging findingsDiagnosisClinical Presentation, Management, and Outcome in Neurolymphomatosis
Kaulen L, Hielscher T, Doubrovinskaia S, Hoffmann D, Kessler T, Traub B, Baehring J, Wick W. Clinical Presentation, Management, and Outcome in Neurolymphomatosis. Neurology 2024, 103: e209698. PMID: 39102613, DOI: 10.1212/wnl.0000000000209698.Peer-Reviewed Original ResearchConceptsPeripheral nervous systemPrimary NLPrognostic factorsDiagnostic yieldFDG-PETMedian overall survivalRituximab-based therapyRituximab-based treatmentNon-Hodgkin's lymphomaManifestation of malignancyNervous systemLog-rank testTumor-directed therapyMultivariate survival analysisCox proportional hazards modelsTreatment of NLConcurrent systemic diseaseIndividual patient dataProportional hazards modelConsensus therapyPainful polyneuropathyLymphomatous infiltrationOverall survivalPerformance statusPrognostic stratificationNeurological complications of medical therapies in haematological malignancies
Baehring J, Soussain C. Neurological complications of medical therapies in haematological malignancies. 2024, 109-122. DOI: 10.1093/med/9780198884903.003.0008.Peer-Reviewed Original ResearchChimeric antigen receptorStem cell transplantationHaematological malignanciesCell transplantationMedical therapyNeurological complicationsAssociated with posterior reversible encephalopathy syndromeAllogeneic stem cell transplantationGraft-versus-host diseasePosterior reversible encephalopathy syndromeRisk of opportunistic infectionsCerebrospinal fluidHaematopoietic stem cell transplantationCentral nervous system involvementComplications of medical therapySpectrum of neurological complicationsT-cell therapyGraft-versus-hostTumor lysis syndromeReversible encephalopathy syndromeDural sinus thrombosisNervous system involvementBispecific monoclonal antibodyAdaptive immune systemSpecific to patientsFavorable Radiographic Response in a Patient With an Oligodendroglioma Treated With Azacitidine and Venetoclax for Acute Myeloid Leukemia
Perez M, Barrionuevo V, Arias C, Baehring J. Favorable Radiographic Response in a Patient With an Oligodendroglioma Treated With Azacitidine and Venetoclax for Acute Myeloid Leukemia. Cureus 2024, 16: e61540. PMID: 38957232, PMCID: PMC11219064, DOI: 10.7759/cureus.61540.Peer-Reviewed Original Research
2023
Imaging metabolism of deuterated glucose in patients with primary brain tumors
Corbin Z, Liu Y, Fulbright R, Thaw-Poon S, Baehring J, Blondin N, Kim P, Omuro A, Chiang V, Moliterno J, Omay S, Piepmeier J, Rothman D, de Graaf R, De Feyter H. Imaging metabolism of deuterated glucose in patients with primary brain tumors. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/0142.Peer-Reviewed Original ResearchNCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.
Horbinski C, Nabors L, Portnow J, Baehring J, Bhatia A, Bloch O, Brem S, Butowski N, Cannon D, Chao S, Chheda M, Fabiano A, Forsyth P, Gigilio P, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Merrell R, Mrugala M, Nagpal S, Nedzi L, Nevel K, Nghiemphu P, Parney I, Patel T, Peters K, Puduvalli V, Rockhill J, Rusthoven C, Shonka N, Swinnen L, Weiss S, Wen P, Willmarth N, Bergman M, Darlow S. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022. Journal Of The National Comprehensive Cancer Network 2023, 21: 12-20. PMID: 36634606, DOI: 10.6004/jnccn.2023.0002.Peer-Reviewed Original ResearchConceptsCentral nervous system cancerNervous system cancersNCCN guidelinesCNS cancersSystem cancersPrimary spinal cord tumorsExtensive brain metastasesNCCN Guidelines InsightsMetastatic spine tumorsPrimary CNS lymphomaSpinal cord tumorsBrain metastasesCNS lymphomaSystemic therapyCord tumorsSpine tumorsLeptomeningeal metastasesSurgical managementCNS tumorsRelevant new dataSpinal ependymomasBrain tumorsCancer panelTumorsCancer
2020
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
Nabors L, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, Butowski N, Campian J, Clark S, Fabiano A, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Horbinski C, Junck L, Kaley T, Kumthekar P, Loeffler J, Mrugala M, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli V, Robins I, Rockhill J, Rusthoven C, Shonka N, Shrieve D, Swinnen L, Weiss S, Wen P, Willmarth N, Bergman M, Darlow S. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2020, 18: 1537-1570. PMID: 33152694, DOI: 10.6004/jnccn.2020.0052.Peer-Reviewed Original ResearchConceptsCentral nervous system cancerNervous system cancersCNS cancersSystem cancersNCCN Clinical Practice GuidelinesMetastatic brain diseaseClinical practice guidelinesNCCN guideline recommendationsCommon intracranial tumorsNCCN guidelinesBrain metastasesGuideline recommendationsGrade IIntracranial tumorsPractice guidelinesPilocytic astrocytomaBrain tumorsAppropriate managementBrain diseasesCancerRadiation therapistsTumorsInterdisciplinary teamGliomasStandard practiceWhole Exome Sequencing Identifies Novel SLIT2 Mutations in Primary CNS Lymphoma (3962)
Kaulen L, Erson-Omay E, Henegariu O, Karschnia P, Huttner A, Gunel M, Baehring J. Whole Exome Sequencing Identifies Novel SLIT2 Mutations in Primary CNS Lymphoma (3962). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.3962.Peer-Reviewed Original ResearchAutoimmune disease-related primary CNS lymphoma: Review of literature and meta-analysis. (3990)
Kaulen L, Karschnia P, Dietrich J, Baehring J. Autoimmune disease-related primary CNS lymphoma: Review of literature and meta-analysis. (3990). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.3990.Peer-Reviewed Original Research
2019
Prognostic Factors and Survival in Primary CNS Lymphoma Patients at Yale (P1.6-013)
Prado I, Barbiero F, Baehring J, Becker K, Corbin Z. Prognostic Factors and Survival in Primary CNS Lymphoma Patients at Yale (P1.6-013). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.p1.6-013.Peer-Reviewed Original Research
2018
DELAYED CEREBRAL PSEUDOANEURYSM FORMATION FROM DISSEMINATION OF ATRIAL MYXOMA (P6.108)
Roque A, Baehring J, Kimbrough T, Huttner A, Traner C, Madri J, Sklar J. DELAYED CEREBRAL PSEUDOANEURYSM FORMATION FROM DISSEMINATION OF ATRIAL MYXOMA (P6.108). Neurology 2018, 90 DOI: 10.1212/wnl.90.15_supplement.p6.108.Peer-Reviewed Original ResearchLeptomeningeal dissemination from low-grade neuroepithelial CNS tumors in adults: a 15-year experience (P6.159)
Karschnia P, Barbiero F, Schwaiblmair M, Piepmeier J, Huttner A, Becker K, Fulbright R, Baehring J. Leptomeningeal dissemination from low-grade neuroepithelial CNS tumors in adults: a 15-year experience (P6.159). Neurology 2018, 90 DOI: 10.1212/wnl.90.15_supplement.p6.159.Peer-Reviewed Original Research